MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.prrv.2025.04.003

Медицинская библиотека · Paediatric respiratory reviews · 2025

Long-acting muscarinic antagonists as add-on treatment for asthma in children under age 12: a systematic review and meta-analysis.

Bolner Gabriel, Rossi Yohanna Idsabella, Dall'Acqua Jonathan Costa, Rossato Artur Vestena, de Oliveira Fabiana Dolovitsch, Bolner Kauê, Fischer Gilberto Bueno, Lukrafka Janice Luisa, Mocelin Helena Teresinha

СтатьяСистематический обзорМетаанализПеревод в очереди

Аннотация

INTRODUCTION

Children under 12 have fewer treatment options for uncontrolled asthma than adolescents and adults. Long-acting muscarinic antagonists (LAMA) can be used as an add-on therapy for asthma in adults, but the evidence in children is unclear.

METHODS

We systematically searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) and observational studies that evaluated LAMA as an add-on therapy to inhaled corticosteroids in asthmatic children younger than 12. We performed a random-effects meta-analysis for lung function, asthma control, and adverse events. Subgroup analyses were performed for different LAMA dosages.

RESULTS

Four RCTs and two observational studies (n = 1210) were included in our systematic review. The pulmonary function tests indicated that LAMA at any dose significantly improved peak FEV1 (MD 86.16 mL; 95 %CI 18.62-153.71; p < 0.01) and FEF25-75 % (MD 0.2518L; 95 %CI 0.1971-0.3064; p < 0.01), while FVC (MD 9.69 mL; 95 %CI -34.57 to 53.95; p = 0.67) remained unchanged. Asthma control measured by the Asthma Control Questionnaire (MD -0.07; 95 %CI -0.08 to -0.06; p < 0.01) also favoured LAMA treatments. Nighttime awakenings and rescue treatment usage showed no significant differences between groups. Using LAMA was also associated with fewer adverse events (RR 0.88; 95 %CI 0.79-0.98; p = 0.021).

CONCLUSION

LAMA are safe and effective for moderate/severe asthma for children aged 6-11. Evidence is still slowly evolving for children younger than 6 years.

Для цитирования: Bolner Gabriel, Rossi Yohanna Idsabella, Dall'Acqua Jonathan Costa, Rossato Artur Vestena, de Oliveira Fabiana Dolovitsch, Bolner Kauê, Fischer Gilberto Bueno, Lukrafka Janice Luisa, Mocelin Helena Teresinha. Long-acting muscarinic antagonists as add-on treatment for asthma in children under age 12: a systematic review and meta-analysis.. Paediatric respiratory reviews. 2025. DOI: 10.1016/j.prrv.2025.04.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.